This is the talk page for discussing improvements to the Selegiline article. This is not a forum for general discussion of the article's subject. |
Article policies
|
Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
Archives: 1Auto-archiving period: 60 days |
This article is rated B-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||||||||||||||||||||
|
Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Selegiline.
|
The contents of the Emsam page were merged into Selegiline. For the contribution history and old versions of the redirected page, please see its history; for the discussion at that location, see its talk page. |
Orally Disintegrating Tabet for Selegiline (Zelapar) approved by FDA edit
Zelapar, produced by Valeant Pharmaceuticals International, was approved by the FDA in June 2006 for the treatment of Parkinson's Disease.